Elijah W. Kushner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elijah W. Kushner has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Allison M. Kehlmann
Mass General Brigham 2 Boston, MA
3 shared publications - Alvin A. Morales-Giron
Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts
3 shared publications - Andreas Varkaris
Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts
3 shared publications - Ankit Singh
Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts
3 shared publications - Aparna Raj Parikh
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
3 shared publications - Brendan Connell
Lahey Hospital and Medical Center 6 Department of Hematology-Oncology Burlington, Massachusetts
3 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents.Significance:This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance.See related commentary by Liu and Gu, p. 620
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents.Significance:This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance.See related commentary by Liu and Gu, p. 620
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S6 from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
Supplementary Figure S1|List of p53 alterations detected in patient 1 at disease progression. Supplementary Figure S2|Mutations surrounding the Y220C crevice were not present before treatment with rezatapopt. Supplementary Figure S3|Acquired p53 alterations render cells insensitive to rezatapopt treatment. Supplementary Figure S4|Acquired p53 alterations render HNSCC cells insensitive to rezatapopt treatment. Supplementary Figure S5|Not all acquired mutations in the Y220C crevice result in p53 loss-offunction. Supplementary Figure S6|Alterations affecting P152 invariably led to resistance to rezatapopt, while some substitutions may retain partial p53 functionality.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S6 from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
Supplementary Figure S1|List of p53 alterations detected in patient 1 at disease progression. Supplementary Figure S2|Mutations surrounding the Y220C crevice were not present before treatment with rezatapopt. Supplementary Figure S3|Acquired p53 alterations render cells insensitive to rezatapopt treatment. Supplementary Figure S4|Acquired p53 alterations render HNSCC cells insensitive to rezatapopt treatment. Supplementary Figure S5|Not all acquired mutations in the Y220C crevice result in p53 loss-offunction. Supplementary Figure S6|Alterations affecting P152 invariably led to resistance to rezatapopt, while some substitutions may retain partial p53 functionality.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 677-685
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents. Significance: This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance. See related commentary by Liu and Gu, p. 620
- 8 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 677-685
Open AccessAcquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents. Significance: This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance. See related commentary by Liu and Gu, p. 620